

Dear colleagues,

First of all I'd like to thank your careful revision of the manuscript and for all your recommendations. I also want to give thanks for your good feedback and positive comments and the interest for publishing it.

Regarding to requested concerns, we have made the following modifications:

- We have changed the full name of EORTC as recommended: European Organization for Research on Treatment of Cancer.
- We have checked carefully all references and corrected some of them, including two which didn't match with the citations (Gomez et al and Lee et al).
- Regarding the SABR-COMET study (The main prospective studies), p value was 0.09, and it was considered as significant difference for the following reason: that study used a randomized phase 2 screening design with a two-sided α of 0.20 and power of 80%, which is higher than the 0.05 level used in phase 3 designs, recognising that positive results should not be considered definitive.
- English language *polishing* has been made by a professional English editor.
- We have described the abbreviation for OMD in the abstract and in the introduction.
- On page 6, “~leading to disseminated disease over time”, we added a reference that is the same as next sentence because it is explained in that article.
- We have corrected some error of spacing and typos.

Thank you very much.

Xabier Mielgo Rubio
Oncology Unit
Hospital Universitary Foundation Alcorcón